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A B S T R A C T
Background: Biochemically, hyperandrogenism is established by elevated circulating levels of free or total serum 
testosterone and an increased free androgen index. Approximately, 60‑80% of women with polycystic ovarian 
syndrome (PCOS) demonstrate elevated circulating androgen levels. Aim: This prospective observational randomized 
study was to investigate the likelihood of using the salivary luteinizing hormone (LH), free testosterone (FT) and 
dehydroepiandrosterone sulfate (DHEAS) levels instead of serum values in diagnosing biochemical hyperandrogenemia in 
women with PCOS. Subjects and Methods: This study was conducted on 75 women having PCOS in addition to 20 normal 
fertile women (control group). Venous blood and salivary samples were taken in the 3rd day of the cycle to measure LH 
and FT and DHEAS levels. Results: Biochemical hyperandrogenemia prevails in 40% of women with PCOS. Salivary levels of 
LH, FT and DHEAS correlate with their corresponding serum values, with a higher sensitivity of salivary more than serum 
approach. Conclusion: Saliva provides a sensitive, simple, reliable, non‑invasive and uncomplicated diagnostic approach for 
biochemical hyperandrogenemia.
KEY WORDS: Biochemical hyperandrogenemia, dehydroepiandrosterone sulfate, luteinizing hormone, polycystic ovarian 
syndrome, saliva, testosterone
INTRODUCTION
Polycystic ovarian syndrome (PCOS) is a widely spread 
disease among females during their reproductive period. 
One of the criteria on which the diagnosis of PCOS is built 
on, is the assessment of testosterone hormone (T), which is 
often elevated in such cases.[1] It is estimated that 60‑80% 
of women with PCOS demonstrate elevated circulating 
androgen levels.[2]
Biochemically, hyperandrogenism is established by elevated 
circulating levels of free or total serum testosterone, 
androstenedione and an increased free androgen index.[3]
Saliva, which offers a non‑invasive and stress‑free alternative 
to plasma and serum, is a widely accepted sample source 
for analysis of steroids and of certain amines and peptides. 
In recent years, numerous publications have described the 
use of salivary hormone analysis in many fields of clinical 
and basic research.[4‑6] Although saliva has not yet become 
a mainstream sample source for hormone analysis, it has 
proven to be reliable and in some cases, even superior to 
other body fluids. Nevertheless, much effort will be required 
in this approach to receive acceptance over the long‑term, 
especially by clinicians.[7]
Sex steroids have been analyzed successfully in saliva for 
years. In assessing the ovarian cycle, saliva samples have 
been demonstrated to enable differentiation between 
the follicular and luteal phase for both estradiol and 
progesterone.[8]
The previous studies showed that salivary T gives a useful 
indication of levels of biologically available androgen in 
hyperandrogenic women.[9] Testosterone is secreted in 
saliva in the free form without.[10]
The aim of this work was to determine the likelihood of 
using saliva more than serum in diagnosing biochemical 
hyperandrogenemia in women with PCOS.
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Both serum and salivary LH were significantly higher in 
PCOS patients than that of the control cases (P values 
were <0.001, in favor of salivary results), as depicted in 
Tables 1 and 2.
FT in both the serum and saliva was significantly higher 
among the PCOS women than the corresponding values 
from the control P = 0.01 and <0.01 respectively, in favor 
of salivary findings.
DHEAS in both the serum and saliva was insignificantly 
higher among the PCOS women than the corresponding 
values of the control.
Table 3 and Figures 1‑3 depict the presence of a 
statistically positive correlation between the salivary 
and serum LH and FT level (P = 0.02). Similarly, there 
is a statistically positive correlation between the salivary 
and serum LH (P = 0.001), the salivary and serum level 
of FT (P = 0.001) and between the salivary and serum 
DHEAS (P = 0.001).
Table 1: Serum levels of LH, testosterone and DHEAS in 
control and PCOS subjects
Serum LH (mIU/ml) Serum FT (ng/dl) Serum DHEAS (ug/ml)
Control PCOS Control PCOS Control PCOS
No. of cases 20 75 20 75 20 75
Mean 3.62 6.36 35.82 48.79 260.8 272.3
SD 2.84 3.43 20.41 24.12 98.8 100.5
t 3.661 2.426 0.461
P 0.00036 0.01087 0.32504
LH – Luteinizing hormone; DHEAS – Dehydroepiandrosterone sulfate; PCOS – Polycystic ovarian 
syndrome; SD – Standard deviation; FT – Free testosterone
Table 2: Salivary levels of LH, testosterone and DHEAS in 







Control PCOS Control PCOS Control PCOS
No. of cases 20 75 20 75 20 75
Mean 2.82 3.63 67.90 72.70 0.63 2.02
SD 0.34 0.54 6.82 9.21 0.91 1.70
t 8.238 2.582 4.916
P 0 0.00657 0
LH – Luteinizing hormone; DHEAS – Dehydroepiandrosterone sulfate; PCOS – Polycystic ovarian 
syndrome; SD – Standard deviation; FT – Free testosterone
Table 3: Correlation between serum and salivary LH, 
FT and DHEAS
r P value
Serum LH 0.874 0.001
Salivary LH
Serum FT 0.562 0.001
Salivary FT
Serum DHEAS 0.542 0.001
Salivary DHEAS
Notice that there is a statistically positive correlation between the salivary and serum LH, FT 
and DHEAS. LH – Luteinizing hormone; DHEAS – Dehydroepiandrosterone sulfate; FT – Free 
testosterone
SUBJECTS AND METHODS
This prospective observational cohort study was conducted 
on 75 women having PCOS, selected from those attending 
the Department of Obstetrics and Gynecology, Tanta 
University Hospital, during the period from November 
2011 to April 2012. All PCOS cases fulfilled the Rotterdam 
revised diagnostic criteria of polycystic ovary syndrome[1] in 
addition to 20 normal fertile women (control group).
All patients included within the study were counseled 
thoroughly about the procedure, including its value and 
hazards, and aim for this study. After this, a written consent 
was obtained and signed by the patient in accordance the 
declaration of Helsinki. Moreover, the ethical committees at 
the department approved the protocol.
The most important inclusion criteria were: Age between 20 
and 35 years, complaining of primary infertility, having no 
ovulation induction drugs during at least the last 3 months 
before the procedure, body mass index between 25 and 
29.9, absence of other causes of infertility evidenced by 
semen analysis and hysterosalpingography.
The most important exclusion criteria were: Age ≥ 35 years, 
history of medical or endocrinological disorders, history of 
abdominal or pelvic surgical operations, history of ovarian 
diseases; tumors, pathological cysts, endometriosis, or 
tuboovarian abscess, history of dental and oral diseases or 
operations, patients receiving any medications, especially 
hormonal therapy.
Methods
The following methods were undertaken for each patient
Full history taking and thorough general and local examination.
Venous blood sample was taken in the 3rd day of the cycle, either 
spontaneous or progestin‑induced withdrawal bleeding, to 
measure luteinizing hormone (LH), free testosterone (FT) and 
dehydroepiandrosterone sulfate (DHEAS) levels.
Salivary sample was collected to measure LH, FT and 
DHEAS levels in the 3rd day of cycle by the enzyme‑linked 
immunosorbent assay.
Analysis of the results was performed using the mean, 
standard deviation, t‑test, analysis of variance, linear 
correlation according to the methods described by Petrie 
and Sabin using statistical product and service solutions] 
software statistical computer package version 12.[11] This 
software allows statistical analysis, data management and 
data documentation. P <0.05 was considered as significant.
RESULTS
The percentage of the biochemical hyperandrogenemia 
among the studied cases with PCOS was 40%.
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Figure 3 reveals that the receiver operating character proves 
that the accuracy of measuring salivary testosterone and LH 
is higher than the corresponding serum values.
DISCUSSIONS
Polycystic ovary syndrome is one of the most important 
causes of female hyperandrogenemia, reflected by elevated 
circulating androgen levels, particularly testosterone. Both 
ovaries and the adrenal glands secrete androgens.[12]
The typical endocrine abnormalities in anovulatory women 
with PCOS are raised serum concentrations of androgens 
and LH, with normal or slightly suppressed serum follicle 
stimulating hormone levels. Approximately, 50% of cases 
with PCOS have raised LH concentrations and approximately 
30% with PCOS have. An elevated total testosterone on spot 
testing.[13]
The results from this standing research revealed that 
biochemical hyperandrogenemia was present in 40% of our 
patients with PCOS, which in turn supports the previous 
suggestion.[2] This finding varies from that of Huanget and 
associates who reported that the overall prevalence of 
hyperandrogenemia in PCOS was 75.3%.[14]
Salivary androstenedione/salivary testosterone ratio may 
be a good indicator of hyperandrogenism in women. 
We also confirm that measurement of androstenedione 
in plasma may be useful in making a diagnosis of PCOS.[15]
Omnia‑Youssef concluded that determination of salivary 
testosterone is a reliable method to detect changes in the 
concentration of available biologically active testosterone 
in the serum. Salivary testosterone provides a sensitive, 
simple, reliable, non‑invasive and uncomplicated diagnostic 
approach for PCOS.[16]
The contemporaneous study proved the presence of a 
significant positive correlation between the salivary and 
serum testosterone (r = 0.506 and P = 0.001). These results 
match with those of many other authors.[8]
In addition, we noticed that serum and salivary testosterone 
were also found to correlate with LH in cases of PCOS. This 
finding agrees with that of other authors.[17]
Finally, we conclude that saliva provides a sensitive, 
simple, reliable, non‑invasive and uncomplicated diagnostic 
approach for biochemical hyperandrogenemia.
Figure 1: Correlation between the salivary and serum LH, testosterone 
(LH – Luteininzing hormone)
Figure 2: Correlation between the salivary and serum DHEAS 
(DHEAS – Degydroepindrosterone sulphate)
Figure 3: The receiver operating character of salivary versus serum LH and FT. (FT – Free testosterone LH – Luteininzing hormone)
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